Metabolic Dysfunction-Associated Steatotic Liver Disease and Atherosclerotic Cardiovascular Disease: Shared Pathophysiology, Biomarkers, and Emerging Therapeutic Strategies

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is increasingly recognized as an important cardiovascular risk modifier. Cardiovascular disease is the leading cause of mortality among individuals with MASLD, reflecting shared pathophysiologic mechanisms with atherosclerotic cardiovascular disease. These include insulin resistance, lipotoxicity, oxidative stress, chronic inflammation, endothelial dysfunction, and progressive fibrogenesis, which contribute to both hepatic disease progression and atherosclerotic plaque development. Noninvasive biomarkers and imaging modalities provide complementary tools for integrated risk assessment. Serum measures of insulin resistance, atherogenic dyslipidemia, inflammation, and composite fibrosis scores are associated with both liver disease severity and cardiovascular risk. Vibration-controlled transient elastography enables noninvasive assessment of hepatic fibrosis and steatosis, while coronary artery calcium scoring is a robust predictor of subclinical atherosclerosis and cardiovascular events. Increasing evidence demonstrates a positive association between hepatic fibrosis severity and coronary artery calcium burden, supporting combined hepatic and cardiovascular evaluation in patients with MASLD. Therapeutic strategies targeting shared cardiometabolic pathways offer a potential dual benefit. Lifestyle modification remains foundational for improving hepatic disease activity and reducing cardiovascular risk. Statins are safe in MASLD and provide established cardiovascular protection. Glucagon-like peptide-1 receptor agonists and other emerging metabolic therapies demonstrate promise in improving liver disease activity while favorably modifying cardiometabolic risk factors. Recognition of MASLD as a systemic cardiometabolic disorder has important implications for cardiovascular risk stratification and multidisciplinary care.

Authors

Institutions

Publication Details

Journal
Cardiology in Review
Published
2026-03-31
DOI
https://doi.org/10.1097/crd.0000000000001259
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metabolic Dysfunction-Associated Steatotic Liver Disease and Atherosclerotic Cardiovascular Disease: Shared Pathophysiology, Biomarkers, and Emerging Therapeutic Strategies

Madison S. Drogy, Shenelle T. Minto, William H. Frishman
Cardiology in Review
Liver Disease Diagnosis and Treatment
article

Metabolic Dysfunction-Associated Steatotic Liver Disease and Atherosclerotic Cardiovascular Disease: Shared Pathophysiology, Biomarkers, and Emerging Therapeutic Strategies

Madison S. Drogy, Shenelle T. Minto, William H. Frishman
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is increasingly recognized as an important cardiovascular risk modifier. Cardiovascular disease is the leading cause of mortality among individuals with MASLD, reflecting shared pathophysiologic mechanisms with atherosclerotic cardiovascular disease. These include insulin resistance, lipotoxicity, oxidative stress, chronic inflammation, endothelial dysfunction, and progressive fibrogenesis, which contribute to both hepatic disease progression and atherosclerotic plaque development. Noninvasive biomarkers and imaging modalities provide complementary tools for integrated risk assessment. Serum measures of insulin resistance, atherogenic dyslipidemia, inflammation, and composite fibrosis scores are associated with both liver disease severity and cardiovascular risk. Vibration-controlled transient elastography enables noninvasive assessment of hepatic fibrosis and steatosis, while coronary artery calcium scoring is a robust predictor of subclinical atherosclerosis and cardiovascular events. Increasing evidence demonstrates a positive association between hepatic fibrosis severity and coronary artery calcium burden, supporting combined hepatic and cardiovascular evaluation in patients with MASLD. Therapeutic strategies targeting shared cardiometabolic pathways offer a potential dual benefit. Lifestyle modification remains foundational for improving hepatic disease activity and reducing cardiovascular risk. Statins are safe in MASLD and provide established cardiovascular protection. Glucagon-like peptide-1 receptor agonists and other emerging metabolic therapies demonstrate promise in improving liver disease activity while favorably modifying cardiometabolic risk factors. Recognition of MASLD as a systemic cardiometabolic disorder has important implications for cardiovascular risk stratification and multidisciplinary care.

Cardiology in Review
New York Medical College (US)
Good health and well-being
Openalex Percentile: Top 10%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.